Top Page
Nova Eye Medical
(OTC:EYE)
Nova Eye Medical (EYE) vs. iShares MSCI Australia ETF (EWA)
Nova Eye Medical Business Overview & Revenue Model
Nova Eye Medical Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 29.27M | 29.27M | 23.32M | 17.02M | 13.38M | 13.39M |
| Gross Profit | 18.89M | 20.07M | 20.19M | 842.00K | -765.00K | 1.77M |
| EBITDA | -6.72M | -8.98M | -5.98M | -14.65M | -7.89M | -3.67M |
| Net Income | -9.06M | -9.06M | -8.79M | -15.29M | -7.50M | -4.36M |
Balance Sheet | ||||||
| Total Assets | 26.50M | 26.50M | 29.88M | 30.36M | 36.63M | 41.99M |
| Cash, Cash Equivalents and Short-Term Investments | 5.05M | 5.05M | 6.15M | 7.42M | 8.00M | 17.80M |
| Total Debt | 3.02M | 3.02M | 3.35M | 1.53M | 1.94M | 3.70M |
| Total Liabilities | 7.54M | 7.54M | 8.55M | 7.17M | 6.23M | 6.66M |
| Stockholders Equity | 18.97M | 18.97M | 21.33M | 23.19M | 30.40M | 35.34M |
Cash Flow | ||||||
| Free Cash Flow | -6.45M | -6.58M | -8.31M | -7.52M | -10.27M | -15.13M |
| Operating Cash Flow | -6.15M | -6.15M | -7.86M | -6.72M | -4.68M | -12.90M |
| Investing Cash Flow | -450.00K | -364.00K | -325.00K | -800.00K | -4.58M | -3.22M |
| Financing Cash Flow | 5.56M | 5.56M | 6.91M | 6.82M | -402.00K | -61.61M |
Nova Eye Medical Technical Analysis
Nova Eye Medical Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$13.43M | -1.63 | -103.74% | ― | 14.84% | 39.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$61.51M | -46.38 | -6.35% | ― | 2.23% | -263.16% | |
45 Neutral | AU$63.44M | ― | -128.19% | ― | -14.25% | -22.83% | |
44 Neutral | AU$176.12M | -16.52 | -70.55% | ― | ― | -257.32% | |
43 Neutral | AU$37.03M | ― | -44.16% | ― | 25.47% | 14.08% | |
41 Neutral | AU$70.02M | -5.38 | -31.98% | ― | 34.20% | -23.90% |
Nova Eye Medical Corporate Events
Nova Eye Medical Limited reported a 32% increase in global sales, excluding China, for the quarter ending September 2025, with revenue reaching US$4.9 million. The company received approval from China’s National Medical Products Administration for its iTrack™ Advance product, which is expected to enhance its market presence in China. Despite slower-than-expected commercial expansion in the USA and Canada, the company reaffirmed its FY26 sales revenue guidance and is targeting improved cash flow and EBITDA breakeven by the second half of FY26.
Nova Eye Medical Limited has announced an upcoming Investor Webinar scheduled for 5 November 2025, where Managing Director Tom Spurling will discuss the company’s quarterly results for Q1 FY26. This event provides an opportunity for shareholders and interested parties to engage with the company’s leadership and gain insights into its financial performance and strategic direction. The announcement highlights Nova Eye Medical’s commitment to transparency and stakeholder engagement, potentially strengthening its position in the medical technology industry.
Nova Eye Medical Limited has announced its Annual General Meeting (AGM) scheduled for November 27, 2025, at The Kent Town Hotel in Adelaide. Shareholders are encouraged to submit questions in advance and can vote either in person or by proxy. This meeting is a crucial event for stakeholders as it provides an opportunity to discuss the company’s strategic direction and operational plans, potentially impacting its market positioning and shareholder relations.
Nova Eye Medical Limited has announced that its Annual General Meeting will take place on November 27, 2025, in Adelaide. This meeting will include the election of directors, with nominations closing on October 9, 2025. This announcement is significant for stakeholders as it outlines the company’s governance timeline and potential changes in leadership, which could impact its strategic direction and operations.
Nova Eye Medical Limited announced the cessation of 100,000 securities due to the expiration of options that were not exercised or converted by July 31, 2025. This cessation of securities may impact the company’s capital structure, potentially influencing its market positioning and shareholder value.
Nova Eye Medical Limited announced the issuance of 333,333 unquoted performance rights under an employee incentive scheme. This move is part of the company’s strategy to align employee interests with corporate goals, potentially enhancing motivation and retention, which could strengthen its position in the competitive ophthalmic market.
Nova Eye Medical Limited has announced the application for quotation of 111,111 ordinary fully paid securities on the Australian Securities Exchange (ASX), under the code EYE. This move is part of an employee incentive scheme and indicates the company’s ongoing efforts to enhance its market presence and operational capabilities, potentially impacting stakeholders by increasing the liquidity and marketability of its shares.
Nova Eye Medical Limited has announced a change in the director’s interest in securities, specifically involving Thomas Anthony Spurling. The change reflects an off-market purchase of 78,273 ordinary shares by Spurling, increasing his direct holding to 1,109,242 shares, while his indirect holding remains unchanged. This adjustment in shareholding could indicate confidence in the company’s strategic direction and potential growth, impacting stakeholders’ perception positively.
Nova Eye Medical Limited has released its financial results for the year ending June 30, 2025, highlighting its ongoing commitment to advancing ophthalmic treatment solutions. The announcement underscores the company’s strategic focus on addressing high intraocular pressure (IOP), which can damage the optic nerve and lead to blindness, by innovating in the field of glaucoma management. This development is expected to enhance Nova Eye Medical’s industry positioning and provide significant implications for stakeholders, particularly in improving patient outcomes and expanding market reach.
Nova Eye Medical Limited has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, highlighting their commitment to transparency and accountability in management practices. This announcement underscores Nova Eye Medical’s dedication to maintaining high standards of corporate governance, potentially strengthening its position in the market and reassuring stakeholders of its operational integrity.
Nova Eye Medical Limited reported a record revenue of A$29.3 million for FY25, marking a 23% increase from the previous year, driven by strong sales of its iTrack™ Advance device. The company showed significant growth in the US market, achieving six consecutive half-years of sales increases and nearing EBITDA positivity, which underscores the effectiveness of its business model. Strategic developments include a potential increase in MIGS market share, regulatory progress in China, and ongoing innovation in drug delivery applications. The company also received government support through a federal grant, reinforcing its position in the eye care industry. Looking ahead, Nova Eye Medical aims for continued sales growth and breakeven EBITDA in the first half of FY26.
Nova Eye Medical Limited reported a 25% increase in revenues from continuing operations, reaching $29,267,000 for the financial year ending June 30, 2025. Despite the revenue growth, the company experienced a 3% increase in net loss from continuing operations, amounting to $9,059,000. This financial performance highlights the company’s ongoing challenges in achieving profitability while expanding its market presence.
Nova Eye Medical Limited announced a change in the director’s interest, with Thomas Anthony Spurling acquiring 300,000 ordinary shares through the conversion of performance rights. This change, approved at the company’s AGM in November 2024, increases Spurling’s direct shareholding to 1,030,969 shares. The adjustment in shareholding reflects the company’s ongoing commitment to aligning director interests with shareholder value, potentially impacting stakeholder perceptions positively.
Nova Eye Medical Limited has announced the application for the quotation of 300,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code EYE. This issuance is part of an employee incentive scheme and is not subject to transfer restrictions, potentially enhancing employee engagement and aligning their interests with company performance. The move is expected to bolster Nova Eye Medical’s market presence and operational capacity, potentially impacting its positioning in the ophthalmic treatment sector.
Nova Eye Medical Limited has announced the quotation of 257,173 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code EYE, effective August 4, 2025. This move is part of an employee incentive scheme, reflecting the company’s ongoing efforts to enhance its market presence and incentivize its workforce, potentially impacting its operational dynamics and stakeholder engagement.